SCHEMBL9895296

SCHEMBL9895296

Cn1nnc(-c2ccccc2F)c1-c1c[nH]cn1

nearest known ligand 0.35

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GRM2 Q14416 1/20 0.35
MBNL1 Q9NR56 1/20 0.35
DHODH Q02127 2/20 0.34
KDM5B Q9UGL1 2/20 0.34
PIM1 P11309 4/20 0.34
NPC1 O15118 1/20 0.33
ALDH1A1 P00352 1/20 0.33
PKM P14618 1/20 0.33
RAB9A P51151 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
PDE2A O00408 1/20 0.33
PDE10A Q9Y233 1/20 0.33
GRM5 P41594 1/20 0.33
ADORA2A P29274 1/20 0.32
IDO1 P14902 1/20 0.32
SLC9A1 P19634 1/20 0.32
KEAP1 Q14145 1/20 0.32
HTT P42858 1/20 0.32
PIP4K2C Q8TBX8 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9895975 0.84 HSD11B1 (0.40) KDM5BNPC1ALDH1A1RAB9APDE2A
SCHEMBL9894870 0.78 MAPK14 (0.40) PIM1
SCHEMBL1949016 0.76 IDO1 (0.47) KDM5BNPC1ALDH1A1PKMRAB9A
SCHEMBL38658489 0.76 IDO1 (0.47) KDM5BNPC1ALDH1A1PKMRAB9A
SCHEMBL14551997 0.72 SLC9A1 (0.47) DHODHIDO1SLC9A1KEAP1HTT
SCHEMBL14551995 0.72 SLC9A1 (0.47) DHODHIDO1SLC9A1KEAP1HTT
SCHEMBL15033463 0.72 TUBB4A (0.36) MBNL1DHODHPIM1NPC1ALDH1A1
SCHEMBL9897091 0.69 PSEN1 (0.37) DHODHNPC1ALDH1A1RAB9AL3MBTL1
SCHEMBL9894693 0.69 KCNN4 (0.39)
SCHEMBL2468922 0.69 PTGS1 (0.47) MBNL1NPC1ALDH1A1RAB9AL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2649064-B1 NOVEL TRIAZOLE COMPOUNDS III HOFFMANN LA ROCHE (CH) 2019-10-02 EP disclosed
EP-2649064-A1 NOVEL TRIAZOLE COMPOUNDS III F. Hoffmann-La Roche AG (CH) 2013-10-16 EP disclosed
US-8466181-B2 1,2,3-triazole-imidazole compounds HOFFMANN-LA ROCHE INC. (US) 2013-06-18 US disclosed
WO-2012076590-A1 NOVEL TRIAZOLE COMPOUNDS III F. HOFFMANN-LA ROCHE AG (CH) 2012-06-14 WO disclosed
US-20120149675-A1 1,2,3-TRIAZOLE-IMIDAZOLECOMPOUNDS HOFFMANN-LA ROCHE INC. 2012-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120149675-A1 1,2,3-TRIAZOLE-IMIDAZOLECOMPOUNDS GABRA5, GABRA1, GABRB1 GRM2 235/4885MBNL1 4333/4885DHODH 4010/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.